Purpose The development of blood biomarkers that reflect Alzheimer's disease (AD)
pathophysiology (phosphorylated tau and amyloid-β) has offered potential as scalable tests …

Cerebrospinal fluid analyses and neuroimaging can identify the underlying pathophysiology
at the earliest stage of some neurodegenerative disorders, but do not have the scalability …

The neuropathological confirmation of amyloid-β (Aβ) plaques and tau neurofibrillary
tangles (NFT) remains the gold standard for a definitive diagnosis of Alzheimer's disease …

Introduction This study investigated the diagnostic and disease‐monitoring potential of
plasma biomarkers in mild cognitive impairment (MCI) and Alzheimer's disease (AD) …

Increased cerebrospinal fluid neurofilament light (NfL) is a recognized biomarker for
neurodegeneration that can also be assessed in blood. Here, we investigate plasma NfL as …

Neurofilament light chain (NfL) is a novel biomarker of neurodegenerative diseases. It is
detectable in the peripheral blood, allowing low-invasive assessment of early signs of …

Alzheimer's disease (AD) pathology is partly characterized by accumulation of aberrant
forms of tau protein. Here we report the results of ADAMANT, a 24-month double-blinded …

Synapses are the site for brain communication where information is transmitted between
neurons and stored for memory formation. Synaptic degeneration is a global and early …

Discovery and development of clinically useful biomarkers for Alzheimer's disease (AD) and
related dementias have been the focus of recent research efforts. While cerebrospinal fluid …

Neurofilament light (NfL) is a marker of neuroaxonal injury, a prominent feature of
Alzheimer's disease. It remains uncertain, however, how it relates to amyloid and tau …